His time at the helm was also marked by a major cyberattack that compromised the data of 190 million people, as well as ...

Lockheed Martin lays off 64 Mass. clean energy workers Lockheed Martin lays off 64 Mass. clean energy workers © 2025 American ...

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Global biopharmaceutical leader GSK PLC has entered into a definitive agreement to acquire efimosfermin, a promising ...

UnitedHealth Group Inc. on May 13 issued an update with two items of notable news, saying that its medical costs are likely ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Andrew Witty is stepping down for "personal reasons" while the Minnesota-based insurer suspends its full-year financial ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British pharma giant said Wednesday that it will pay the ...